Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-23T09:22:17.111Z Has data issue: false hasContentIssue false
  • English
  • Français

Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants

Published online by Cambridge University Press:  26 April 2018

Bradley C. Johnston ,
Lyubov Lytvyn ,
Calvin Ka-Fung Lo ,
Stephen J. Allen ,
Duolao Wang ,
Hania Szajewska ,
Mark Miller ,
Stephan Ehrhardt ,
John Sampalis  and
Deniz G. Duman
...Show all authors
Bradley C. Johnston*
Affiliation:
Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Lyubov Lytvyn
Affiliation:
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
Calvin Ka-Fung Lo
Affiliation:
McMaster University, Hamilton, Ontario, Canada
Stephen J. Allen
Affiliation:
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Duolao Wang
Affiliation:
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Hania Szajewska
Affiliation:
Department of Pediatrics, The Medical University of Warsaw, Warsaw, Poland
Mark Miller
Affiliation:
McGill University, Montreal, Québec, Canada
Stephan Ehrhardt
Affiliation:
Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
John Sampalis
Affiliation:
McGill University, Montreal, Québec, Canada
Deniz G. Duman
Affiliation:
Department of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkey
Pietro Pozzoni
Affiliation:
Department of Internal Medicine, A Manzoni Hospital AO Provincia di Lecco, Lecco, Italy
Agostino Colli
Affiliation:
Department of Internal Medicine, A Manzoni Hospital AO Provincia di Lecco, Lecco, Italy
Elisabet Lönnermark
Affiliation:
Department of Infectious Diseases, Gothenburg University, Göteborg, Sweden
Christian P. Selinger
Affiliation:
Department of Gastroenterology, St James University Hospital, Leeds, United Kingdom
Samford Wong
Affiliation:
National Spinal Injuries Center, Stoke Mandeville Hospital, Aylesbury, United Kingdom
Susan Plummer
Affiliation:
Research and Development Department, Cultech Ltd, Port Talbot, United Kingdom
Mary Hickson
Affiliation:
Nutrition and Dietetic Research Group, Plymouth University, United Kingdom
Ruzha Pancheva
Affiliation:
Department of Hygiene, Medical University, Varna, Bulgaria
Sandra Hirsch
Affiliation:
Instituto de Nutrición y Tecnología de los Alimentos, University of Chile, Santiago, Chile
Bengt Klarin
Affiliation:
Department of Anesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden
Joshua Z Goldenberg
Affiliation:
Bastyr University Research Institute, Kenmore, Washington, United States
Li Wang
Affiliation:
Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
Lawrence Mbuagbaw
Affiliation:
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
Gary Foster
Affiliation:
St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada
Anna Maw
Affiliation:
Division of Hospital Medicine, Department of Medicine, University of Colorado, Denver, Colorado, United States
Behnam Sadeghirad
Affiliation:
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
Lehana Thabane
Affiliation:
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
Dominik Mertz
Affiliation:
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada Department of Medicine, McMaster University, Hamilton, Ontario, Canada
*
Address correspondence to Bradley C. Johnston, PhD, Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Centre for Clinical Research, Room 404, 5790 University Avenue, Halifax, Nova Scotia, Canada, B3H 1V7 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

To determine whether probiotic prophylaxes reduce the odds of Clostridium difficile infection (CDI) in adults and children.

DESIGN

Individual participant data (IPD) meta-analysis of randomized controlled trials (RCTs), adjusting for risk factors.

METHODS

We searched 6 databases and 11 grey literature sources from inception to April 2016. We identified 32 RCTs (n=8,713); among them, 18 RCTs provided IPD (n=6,851 participants) comparing probiotic prophylaxis to placebo or no treatment (standard care). One reviewer prepared the IPD, and 2 reviewers extracted data, rated study quality, and graded evidence quality.

RESULTS

Probiotics reduced CDI odds in the unadjusted model (n=6,645; odds ratio [OR] 0.37; 95% confidence interval [CI], 0.25–0.55) and the adjusted model (n=5,074; OR, 0.35; 95% CI, 0.23–0.55). Using 2 or more antibiotics increased the odds of CDI (OR, 2.20; 95% CI, 1.11–4.37), whereas age, sex, hospitalization status, and high-risk antibiotic exposure did not. Adjusted subgroup analyses suggested that, compared to no probiotics, multispecies probiotics were more beneficial than single-species probiotics, as was using probiotics in clinical settings where the CDI risk is ≥5%. Of 18 studies, 14 reported adverse events. In 11 of these 14 studies, the adverse events were retained in the adjusted model. Odds for serious adverse events were similar for both groups in the unadjusted analyses (n=4,990; OR, 1.06; 95% CI, 0.89–1.26) and adjusted analyses (n=4,718; OR, 1.06; 95% CI, 0.89–1.28). Missing outcome data for CDI ranged from 0% to 25.8%. Our analyses were robust to a sensitivity analysis for missingness.

CONCLUSIONS

Moderate quality (ie, certainty) evidence suggests that probiotic prophylaxis may be a useful and safe CDI prevention strategy, particularly among participants taking 2 or more antibiotics and in hospital settings where the risk of CDI is ≥5%.

TRIAL REGISTRATION

PROSPERO 2015 identifier: CRD42015015701

Infect Control Hosp Epidemiol 2018;771–781

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 7 , July 2018 , pp. 771 - 781
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Dubberke, ER, Olsen, MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012;55(Suppl 2):S88–S92.Google Scholar
2. Freeman, J, Bauer, MP, Baines, SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529–549.Google Scholar
3. Dubberke, ER, Butler, AM, Reske, KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008;14:1031–1038.Google Scholar
4. Johnson, S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403–410.Google Scholar
5. Lessa, FC, Mu, Y, Bamberg, WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–834.Google Scholar
6. Slimings, C, Riley, TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881–891.Google Scholar
7. Bauer, MP, Notermans, DW, Van Benthem, BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011;377(9759):63–73.CrossRefGoogle ScholarPubMed
8. Lessa, FC, Gould, CV, McDonald, LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55(Suppl 2):S65–S70.Google Scholar
9. Louie, TJ, Miller, MA, Crook, DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013;61:222–230.Google Scholar
10. Vesteinsdottir, I, Gudlaugsdottir, S, Einarsdottir, R, Kalaitzakis, E, Sigurdardottir, O, Bjornsson, ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 2012;31:2601–2610.Google Scholar
11. Hill, C, Guarner, F, Reid, G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506–514.Google Scholar
12. Goldenberg, JZ, Ma, SS, Saxton, JD, et al. Probiotics for the prevention of Clostridium difficile associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095. doi: 10.1002/14651858.CD006095.pub3.Google Scholar
13. Goldenberg, JZ, Yap, C, Lytvyn, L, Lo, CK, Beardsley, J, Mertz, D, Johnston, BC. Probiotics for the prevention of Clostridium difficile associated diarrhea in adults and children. Cochrane Database Syst Rev 2017:12:CD006095.Google Scholar
14. Lytvyn, L, Mertz, D, Sadeghirad, B, Alaklobi, F, Selva, A, Alonso-Coello, P, Johnston, BC. Prevention of Clostridium difficile infection: a systematic survey of clinical practice guidelines. Infect Control Hosp Epidemiol 2016;37:901–908.CrossRefGoogle ScholarPubMed
15. Carrico, R, Bryant, K, Lessa, F, et al. Guide to preventing Clostridium difficile infections. Association for Professionals in Infection Control and Epidemiology website. http://apic.org/Resource_/EliminationGuideForm/e3a85b7e-7ad8-4ab6-9892- 54aef516cf10/File/2013CDiffFinal.pdf. Published 2013. Accessed August 14, 2017.Google Scholar
16. Dubberke, ER, Carling, P, Carrico, R, et al. Strategies to prevent Clostridium difficile infections in acute-care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:628–645.Google Scholar
17. Surawicz, CM, Brandt, LJ, Binion, DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478–498.Google Scholar
18. Vonberg, RP, Kuijper, E, Wilcox, M, et al. Infection control measures to limit the spread of Clostridium difficile . Clin Microbiol Infect 2008;14(s5):2–20.Google Scholar
19. Hawkey, P, Bain, L, Borriello, P, et al. Clostridium difficile infection: how to deal with the problem. London: Public Health England and Department of Health; 2008.Google Scholar
20. Debast, S, Bauer, M, Kuijper, E. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(s2):1–26.Google Scholar
21. Lytvyn, L, Mertz, D, Thabane, L, et al. Probiotics for the prevention of Clostridium difficile infection in adults and children: an individual patient data meta-analysis. PROSPERO: International prospective register of systematic reviews. Master’s thesis, McMaster University. 2015. doi: 10.15124/CRD42015015701.Google Scholar
22. Bartlett, JG, Gerding, DN. Clinical recognition and diagnosis of Clostridium difficile Infection. Clin Infect Dis 2008;46(Suppl 1):S12–S18.Google Scholar
23. Higgins, J, Altman, DG, Gøtzsche, PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011:343.Google Scholar
24. Guyatt, GH, Oxman, AD, Vist, GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–926.Google Scholar
25. Egger, M, Smith, GD, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–634.CrossRefGoogle ScholarPubMed
26. Deeks, JJ, Higgins, J, Altman, DG. Analysing data and undertaking meta‐analyses. In: The Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester, UK: Wiley & Sons; 2008. Pp. 243–296.Google Scholar
27. Johnston, BC, Goldenberg, JZ, Vandvik, PO, Sun, X, Guyatt, GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011;9(11).Google Scholar
28. Gerding, DN, Olson, MM, Peterson, LR, et al. Clostridium difficile—associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95–100.Google Scholar
29. Gao, XW, Mubasher, M, Fang, CY, Reifer, C, Miller, LE. Dose–response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636–1641.Google Scholar
30. Duman, DG, Bor, S, Özütemiz, Ö, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005;17:1357–1361.Google Scholar
31. Bravo, MV, Bunout, D, Leiva, L, et al. Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment. [In Spanish.] Revista Medica de Chile 2008;136:981–988.Google Scholar
32. Kotowska, M, Albrecht, P, Szajewska, H. Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea in children: a randomized double‐blind placebo‐controlled trial. Aliment Pharmacol Ther 2005;21:583–590.Google Scholar
33. Pozzoni, P, Riva, A, Bellatorre, AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012;107:922–931.Google Scholar
34. Hickson, M, D’Souza, AL, Muthu, N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo-controlled trial. BMJ 2007;335(7610):80.Google Scholar
35. Klarin, B, Wullt, M, Palmquist, I, Molin, G, Larsson, A, Jeppsson, B. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand 2008;52:1096–1102.Google Scholar
36. Miller, M. Results of 2 prospective randomized studies of Lactobacillus GG to prevent C. difficile infection in hospitalized adults receiving antibiotics; 2008a.Google Scholar
37. Miller, M. Results of 2 prospective randomized studies of Lactobacillus GG to prevent C. difficile infection in hospitalized adults receiving antibiotics; 2008b.Google Scholar
38. Plummer, S, Weaver, MA, Harris, JC, Dee, P, Hunter, J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2010;7:59–62.Google Scholar
39. Psaradellis, E, Sampalis, J, Rampakakis, E. Efficacy of BIO K+ CL1285® in the reduction of antibiotic associated diarrhea–a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 2010;6:56–64.Google Scholar
40. Selinger, C, Bell, A, Cairns, A, Lockett, M, Sebastian, S, Haslam, N. Probiotic VSL# 3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect 2013;84:159–165.Google Scholar
41. Allen, SJ, Wareham, K, Wang, D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013;382(9900):1249–1257.Google Scholar
42. Wong, S, Jamous, A, O’Driscoll, J, et al. A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Brit J Nutr 2013;111:672–678.Google Scholar
43. Georgieva, M, Pancheva, R, Rasheva, N, Usheva, N, Ivanova, L, Koleva, K. Use of the probiotic Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated infections in hospitalized Bulgarian children: a randomized controlled trial. J IMAB Annual Proceeding (Scientific Papers) 2015;21(4):895–900.Google Scholar
44. Ehrhardt, S, Guo, N, Hinz, R, et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis 2016;3(1):ofw011.Google Scholar
45. Lönnermark, E, Friman, V, Lappas, G, Sandberg, T, Berggren, A, Adlerberth, I. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol 2010;44:106–112.Google Scholar
46. Ruszczyński, M, Radzikowski, A, Szajewska, H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic‐associated diarrhoea in children. Aliment Pharmacol Ther 2008;28:154–161.Google Scholar
47. Hempel, S, Newberry, S, Ruelaz, A, et al. Safety of probiotics to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011:1–645.Google Scholar
48. Colli, A, Pozzoni, P, Conte, D, Casazza, G. Response to Kolber et al. Am J Gastroenterol 2014;109:1082–1083.Google Scholar
49. Brown, KA, Fisman, DN, Moineddin, R, Daneman, N. The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study. PLoS One 2014;9:e105454.Google Scholar
50. Szajewska, H. Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. Eur J Pediatr 2014;173:975.Google Scholar
51. Zawistowska-Rojek, A, Zareba, T, Mrówka, A, Tyski, S. Assessment of the microbiological status of probiotic products. Pol J Microbiol 2016;65:97–104.Google Scholar
52. Thomas, D, Radji, S, Benedetti, A. Systematic review of methods for individual patient data meta-analysis with binary outcomes. BMC Med Res Method 2014;14:79.Google Scholar
53. Brown, K, Valenta, K, Fisman, D, Simor, A, Daneman, N. Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med 2015;175:626–633.Google Scholar
Supplementary material: File

Johnston et al. supplementary material 1

Johnston et al. supplementary material

Download Johnston et al. supplementary material 1(File)
File 4.3 MB